<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02882581</url>
  </required_header>
  <id_info>
    <org_study_id>2016-000132-18</org_study_id>
    <nct_id>NCT02882581</nct_id>
  </id_info>
  <brief_title>Metformin in Breast Cancer, Visualized With Positron Emission Tomography</brief_title>
  <official_title>Metformin in Breast Cancer, Visualized With Positron Emission Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general purpose of the trial is to investigate whether metformin is taken up into the
      breast tumor. Studies in the last few years have shown an effect of metformin on cell
      proliferation on breast cancer. It is though unclear whether the effect on tumor is direct,
      indirect or a combination of the two. The investigators plan to:

        -  investigate if metformin is taken up in breast cancer using our novel 11C-metformin
           tracer and positron emission tomography (PET)

        -  investigate whether the uptake is correlated to the amounts of organic cation
           transporters (OCT1-3, MATE 1 &amp;2 and PMAT) using quantitive polymerase chain reaction
           (qPCR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>11C-metformin uptake in breast cancer. Single center, single dose, open-label.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin uptake in breast cancer</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>11C-metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants allocated to the study will be included in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>11C-metformin</intervention_name>
    <description>400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.</description>
    <arm_group_label>11C-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 50 years

          -  C. mammae

          -  Tumor size: &gt; 10 mm in diameter

          -  Unilateral cancer

          -  WHO performance status 0-1

        Exclusion Criteria:

          -  Severe heart- or kidney failure

          -  Pregnant or breast feeding

          -  If the patient is found not eligible for participation in the study p√• principal
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Jessen, Prof,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Pharmacology, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elias IO Sundelin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Medicine, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nuclear Medicine &amp; PET-center, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Elias Immanuel Ordell Sundelin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Organic cation transporter</keyword>
  <keyword>Multidrug and toxin extrusion</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

